Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
Investors appear to be betting that a key regulatory approval is close at hand.
The maker of continuous glucose monitoring systems for diabetes treatment is a meme stock with some fundamental support.
No podcast episodes available.
SENS earnings call for the period ending June 30, 2019.
SENS earnings call for the period ending March 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
